Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.

Cephalalgia : an international journal of headache

Tchivileva IE, Ohrbach R, Fillingim RB, Lim PF, Giosia MD, Ribeiro-Dasilva M, Campbell JH, Hadgraft H, Willis J, Arbes SJ, Slade GD.
PMID: 33560875
Cephalalgia. 2021 Jun;41(7):839-850. doi: 10.1177/0333102421989268. Epub 2021 Feb 09.

INTRODUCTION: The migraine-preventive drug propranolol is efficacious in reducing pain from temporomandibular disorder, suggesting potential modifying or mediating effects of comorbid migraine.METHODS: In this randomized controlled trial, myofascial temporomandibular disorder patients were treated with propranolol or placebo for 9...

Cite
Tchivileva IE, Ohrbach R, Fillingim RB, et al. Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. Cephalalgia. 2021;41(7):839-850doi: 10.1177/0333102421989268.
Tchivileva, I. E., Ohrbach, R., Fillingim, R. B., Lim, P. F., Giosia, M. D., Ribeiro-Dasilva, M., Campbell, J. H., Hadgraft, H., Willis, J., Arbes, S. J., & Slade, G. D. (2021). Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. Cephalalgia : an international journal of headache, 41(7), 839-850. https://doi.org/10.1177/0333102421989268
Tchivileva, Inna E, et al. "Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial." Cephalalgia : an international journal of headache vol. 41,7 (2021): 839-850. doi: https://doi.org/10.1177/0333102421989268
Tchivileva IE, Ohrbach R, Fillingim RB, Lim PF, Giosia MD, Ribeiro-Dasilva M, Campbell JH, Hadgraft H, Willis J, Arbes SJ, Slade GD. Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. Cephalalgia. 2021 Jun;41(7):839-850. doi: 10.1177/0333102421989268. Epub 2021 Feb 09. PMID: 33560875; PMCID: PMC8166404.
Copy Download .nbib Format: NLM
Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database.

Cardiology in the young

Villarreal EG, Farias JS, Tweddell JS, Loomba RS, Flores S.
PMID: 34233773
Cardiol Young. 2021 Jul 08;1-5. doi: 10.1017/S1047951121002638. Epub 2021 Jul 08.

INTRODUCTION: In patients with right ventricular diastolic dysfunction after complete repair of tetralogy of Fallot, some employ the use of beta-blockade. The theoretical benefit of this therapy is felt to be one of the two: 1) reduction in heart...

Cite
Villarreal EG, Farias JS, Tweddell JS, et al. Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database. Cardiol Young. 2021;1-5doi: 10.1017/S1047951121002638.
Villarreal, E. G., Farias, J. S., Tweddell, J. S., Loomba, R. S., & Flores, S. (2021). Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database. Cardiology in the young, 1-5. https://doi.org/10.1017/S1047951121002638
Villarreal, Enrique G, et al. "Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database." Cardiology in the young vol. (2021): 1-5. doi: https://doi.org/10.1017/S1047951121002638
Villarreal EG, Farias JS, Tweddell JS, Loomba RS, Flores S. Beta-blocker use after complete repair of tetralogy of Fallot: an analysis of a national database. Cardiol Young. 2021 Jul 08;1-5. doi: 10.1017/S1047951121002638. Epub 2021 Jul 08. PMID: 34233773.
Copy Download .nbib Format: NLM
Hypertension and Male Fertility.

The world journal of men's health

Guo D, Li S, Behr B, Eisenberg ML.
PMID: 28868816
World J Mens Health. 2017 Aug;35(2):59-64. doi: 10.5534/wjmh.2017.35.2.59.

As the age of paternity rises in the developed world, issues of chronic disease may affect prospective fathers. Given the high prevalence of hypertension, researchers have begun to explore the relationship between hypertensive disease and male fertility. The current...

Cite
Guo D, Li S, Behr B, et al. Hypertension and Male Fertility. World J Mens Health. 2017;35(2):59-64doi: 10.5534/wjmh.2017.35.2.59.
Guo, D., Li, S., Behr, B., & Eisenberg, M. L. (2017). Hypertension and Male Fertility. The world journal of men's health, 35(2), 59-64. https://doi.org/10.5534/wjmh.2017.35.2.59
Guo, David, et al. "Hypertension and Male Fertility." The world journal of men's health vol. 35,2 (2017): 59-64. doi: https://doi.org/10.5534/wjmh.2017.35.2.59
Guo D, Li S, Behr B, Eisenberg ML. Hypertension and Male Fertility. World J Mens Health. 2017 Aug;35(2):59-64. doi: 10.5534/wjmh.2017.35.2.59. PMID: 28868816; PMCID: PMC5583372.
Copy Download .nbib Format: NLM
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.

Circulation

Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T.
PMID: 33993702
Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16.

BACKGROUND: Adjuvant breast cancer therapy containing anthracyclines with or without anti-human epidermal growth factor receptor-2 antibodies and radiotherapy is associated with cancer treatment-related cardiac dysfunction. In the PRADA trial (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy), concomitant...

Cite
Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021;143(25):2431-2440doi: 10.1161/CIRCULATIONAHA.121.054698.
Heck, S. L., Mecinaj, A., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W., Gravdehaug, B., Røsjø, H., Steine, K., Geisler, J., Gulati, G., & Omland, T. (2021). Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation, 143(25), 2431-2440. https://doi.org/10.1161/CIRCULATIONAHA.121.054698
Heck, Siri Lagethon, et al. "Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol." Circulation vol. 143,25 (2021): 2431-2440. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054698
Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16. PMID: 33993702; PMCID: PMC8212877.
Copy Download .nbib Format: NLM
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine.

Circulation

McMurray JJV, Packer M.
PMID: 33378214
Circulation. 2021 Mar 02;143(9):875-877. doi: 10.1161/CIRCULATIONAHA.120.052926. Epub 2020 Dec 30.

No abstract available.

Cite
McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2020;143(9):875-877doi: 10.1161/CIRCULATIONAHA.120.052926.
McMurray, J. J. V., & Packer, M. (2021). How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation, 143(9), 875-877. https://doi.org/10.1161/CIRCULATIONAHA.120.052926
McMurray, John J V, and Packer, Milton. "How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine." Circulation vol. 143,9 (2021): 875-877. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.052926
McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2021 Mar 02;143(9):875-877. doi: 10.1161/CIRCULATIONAHA.120.052926. Epub 2020 Dec 30. PMID: 33378214.
Copy Download .nbib Format: NLM
Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis.

Clinical epidemiology

Balla HZ, Cao Y, Ström JO.
PMID: 33762851
Clin Epidemiol. 2021 Mar 16;13:225-236. doi: 10.2147/CLEP.S268105. eCollection 2021.

INTRODUCTION: Cardiovascular events and infections are common in the acute phase after stroke. It has been suggested that these complications may be associated with excessive sympathetic activation due to the stroke, and that beta-adrenergic antagonists (beta-blockers) therefore may be...

Cite
Balla HZ, Cao Y, Ström JO. Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis. Clin Epidemiol. 2021;13:225-236doi: 10.2147/CLEP.S268105.
Balla, H. Z., Cao, Y., & Ström, J. O. (2021). Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis. Clinical epidemiology, 13225-236. https://doi.org/10.2147/CLEP.S268105
Balla, Hajnal Zsuzsanna, et al. "Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis." Clinical epidemiology vol. 13 (2021): 225-236. doi: https://doi.org/10.2147/CLEP.S268105
Balla HZ, Cao Y, Ström JO. Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis. Clin Epidemiol. 2021 Mar 16;13:225-236. doi: 10.2147/CLEP.S268105. eCollection 2021. PMID: 33762851; PMCID: PMC7982440.
Copy Download .nbib Format: NLM
Prescription of anti-anginal drugs in relation to exercise tests and coronary angiography. A 1-year population-based study of two Danish counties.

European journal of internal medicine

Niemann T, Toftegaard Nielsen T, Thorsgaard N, Andersen TF, Lous J.
PMID: 12446195
Eur J Intern Med. 2002 Dec;13(8):500-506. doi: 10.1016/s0953-6205(02)00159-0.

BACKGROUND: The cardiac diagnostic examination activity in a population should ideally mirror age and gender characteristics of the prevalence of ischemic heart disease. In this study, the prescription of anti-anginal drugs in relation to morbidity and mortality brought on...

Cite
Niemann T, Toftegaard Nielsen T, Thorsgaard N, et al. Prescription of anti-anginal drugs in relation to exercise tests and coronary angiography. A 1-year population-based study of two Danish counties. Eur J Intern Med. 2002;13(8):500-506doi: 10.1016/s0953-6205(02)00159-0.
Niemann, T., Toftegaard Nielsen, T., Thorsgaard, N., Andersen, T. F., & Lous, J. (2002). Prescription of anti-anginal drugs in relation to exercise tests and coronary angiography. A 1-year population-based study of two Danish counties. European journal of internal medicine, 13(8), 500-506. https://doi.org/10.1016/s0953-6205(02)00159-0
Niemann, Troels, et al. "Prescription of anti-anginal drugs in relation to exercise tests and coronary angiography. A 1-year population-based study of two Danish counties." European journal of internal medicine vol. 13,8 (2002): 500-506. doi: https://doi.org/10.1016/s0953-6205(02)00159-0
Niemann T, Toftegaard Nielsen T, Thorsgaard N, Andersen TF, Lous J. Prescription of anti-anginal drugs in relation to exercise tests and coronary angiography. A 1-year population-based study of two Danish counties. Eur J Intern Med. 2002 Dec;13(8):500-506. doi: 10.1016/s0953-6205(02)00159-0. PMID: 12446195.
Copy Download .nbib Format: NLM
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.

Circulation

Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T.
PMID: 33993702
Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16.

BACKGROUND: Adjuvant breast cancer therapy containing anthracyclines with or without anti-human epidermal growth factor receptor-2 antibodies and radiotherapy is associated with cancer treatment-related cardiac dysfunction. In the PRADA trial (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy), concomitant...

Cite
Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021;143(25):2431-2440doi: 10.1161/CIRCULATIONAHA.121.054698.
Heck, S. L., Mecinaj, A., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W., Gravdehaug, B., Røsjø, H., Steine, K., Geisler, J., Gulati, G., & Omland, T. (2021). Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation, 143(25), 2431-2440. https://doi.org/10.1161/CIRCULATIONAHA.121.054698
Heck, Siri Lagethon, et al. "Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol." Circulation vol. 143,25 (2021): 2431-2440. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054698
Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16. PMID: 33993702; PMCID: PMC8212877.
Copy Download .nbib Format: NLM
Systolic heart failure: knowledge gaps, misconceptions, and future directions.

The Ochsner journal

Samson R, Ramachandran R, Le Jemtel TH.
PMID: 25598722
Ochsner J. 2014;14(4):569-75.

BACKGROUND: Systolic heart failure is the final manifestation of several cardiovascular conditions. The 2001 American College of Cardiology/American Heart Association guidelines depicting the progression of heart failure (HF) from stage A through stage D are aimed at the early...

Cite
Samson R, Ramachandran R, Le Jemtel TH. Systolic heart failure: knowledge gaps, misconceptions, and future directions. Ochsner J. 2014;14(4):569-75
Samson, R., Ramachandran, R., & Le Jemtel, T. H. (2014). Systolic heart failure: knowledge gaps, misconceptions, and future directions. The Ochsner journal, 14(4), 569-75.
Samson, Rohan, et al. "Systolic heart failure: knowledge gaps, misconceptions, and future directions." The Ochsner journal vol. 14,4 (2014): 569-75.
Samson R, Ramachandran R, Le Jemtel TH. Systolic heart failure: knowledge gaps, misconceptions, and future directions. Ochsner J. 2014;14(4):569-75. PMID: 25598722; PMCID: PMC4295734.
Copy Download .nbib Format: NLM
Decatecholaminization and calcium sensitizers in critically ill patients.

Research in cardiovascular medicine

Golzari SE, Mahmoodpoor A.
PMID: 25478531
Res Cardiovasc Med. 2014 Feb;3(1):e16714. doi: 10.5812/cardiovascmed.16714. Epub 2014 Feb 24.

No abstract available.

Cite
Golzari SE, Mahmoodpoor A. Decatecholaminization and calcium sensitizers in critically ill patients. Res Cardiovasc Med. 2014;3(1):e16714doi: 10.5812/cardiovascmed.16714.
Golzari, S. E., & Mahmoodpoor, A. (2014). Decatecholaminization and calcium sensitizers in critically ill patients. Research in cardiovascular medicine, 3(1), e16714. https://doi.org/10.5812/cardiovascmed.16714
Golzari, Samad E J, and Mahmoodpoor, Ata. "Decatecholaminization and calcium sensitizers in critically ill patients." Research in cardiovascular medicine vol. 3,1 (2014): e16714. doi: https://doi.org/10.5812/cardiovascmed.16714
Golzari SE, Mahmoodpoor A. Decatecholaminization and calcium sensitizers in critically ill patients. Res Cardiovasc Med. 2014 Feb;3(1):e16714. doi: 10.5812/cardiovascmed.16714. Epub 2014 Feb 24. PMID: 25478531; PMCID: PMC4253748.
Copy Download .nbib Format: NLM
The Sedative Effect of Propranolol on Critically Ill Patients: A Case Series.

Frontiers in medicine

Shiotsuka J, Steel A, Downar J.
PMID: 28523268
Front Med (Lausanne). 2017 May 04;4:44. doi: 10.3389/fmed.2017.00044. eCollection 2017.

INTRODUCTION: Recent studies have examined the effectiveness of alpha-2 adrenergic agonists for controlling delirium and agitation. Propranolol, a non-selective beta-adrenergic antagonist with good penetration of the blood-brain barrier, has not been investigated for this purpose.MATERIALS AND METHODS: We retrospectively...

Cite
Shiotsuka J, Steel A, Downar J. The Sedative Effect of Propranolol on Critically Ill Patients: A Case Series. Front Med (Lausanne). 2017;4:44doi: 10.3389/fmed.2017.00044.
Shiotsuka, J., Steel, A., & Downar, J. (2017). The Sedative Effect of Propranolol on Critically Ill Patients: A Case Series. Frontiers in medicine, 444. https://doi.org/10.3389/fmed.2017.00044
Shiotsuka, Junji, et al. "The Sedative Effect of Propranolol on Critically Ill Patients: A Case Series." Frontiers in medicine vol. 4 (2017): 44. doi: https://doi.org/10.3389/fmed.2017.00044
Shiotsuka J, Steel A, Downar J. The Sedative Effect of Propranolol on Critically Ill Patients: A Case Series. Front Med (Lausanne). 2017 May 04;4:44. doi: 10.3389/fmed.2017.00044. eCollection 2017. PMID: 28523268; PMCID: PMC5415564.
Copy Download .nbib Format: NLM
Management of anesthesia in unspecified extra-adrenal pheochromocytoma patient who used beta-blocker.

Saudi journal of anaesthesia

Ozer AB, Demirel I, Duzgol O, Ayten R, Erhan OL.
PMID: 25538499
Saudi J Anaesth. 2014 Nov;8:S105-8. doi: 10.4103/1658-354X.144088.

An operation was planned for a female patient aged 59 for intra-abdominal mass. The patient was using nebivolol for hypertension. Blood pressure (BP) of the patient was raised to 200/130 mmHg during anesthesia induction. BP was gradually reduced by...

Cite
Ozer AB, Demirel I, Duzgol O, et al. Management of anesthesia in unspecified extra-adrenal pheochromocytoma patient who used beta-blocker. Saudi J Anaesth. 2014;8:S105-8doi: 10.4103/1658-354X.144088.
Ozer, A. B., Demirel, I., Duzgol, O., Ayten, R., & Erhan, O. L. (2014). Management of anesthesia in unspecified extra-adrenal pheochromocytoma patient who used beta-blocker. Saudi journal of anaesthesia, 8S105-8. https://doi.org/10.4103/1658-354X.144088
Ozer, Ayse Belin, et al. "Management of anesthesia in unspecified extra-adrenal pheochromocytoma patient who used beta-blocker." Saudi journal of anaesthesia vol. 8 (2014): S105-8. doi: https://doi.org/10.4103/1658-354X.144088
Ozer AB, Demirel I, Duzgol O, Ayten R, Erhan OL. Management of anesthesia in unspecified extra-adrenal pheochromocytoma patient who used beta-blocker. Saudi J Anaesth. 2014 Nov;8:S105-8. doi: 10.4103/1658-354X.144088. PMID: 25538499; PMCID: PMC4268506.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries